All In Biotech

Drug Trial Radar · NCT04747964

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

A Phase 1,Multi-center, Randomized, Open, Single-dose Escalation Design to Evaluate the Safety, Tolerability and Pharmacodynamics of STSP-0601 for Injection in Patients With Inhibitory Hemophilia

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jan 15, 2020

Primary completion

Apr 19, 2021

Study completion Apr 19, 2021

Sponsor

Sponsor type
Industry
First posted
Feb 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the pharmacokinetics and pharmacodynamics of STSP-0601 at six dose levels. The results will help identify the most optimal doses to treat bleedings in hemophilia patients with inhibitors.

Conditions

  • Hemophilia

Interventions

  • STSP-0601 for InjectionDrug

    Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements

  • STSP-0601 for InjectionDrug

    Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements

  • STSP-0601 for InjectionDrug

    Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements

  • STSP-0601 for InjectionDrug

    Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements

  • STSP-0601 for InjectionDrug

    Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements

  • STSP-0601 for InjectionDrug

    Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects of adverse eventsTime frame: Baseline to Day 8
  2. Number of subjects With Significant Abnormal Physical ExaminationTime frame: Baseline to Day 8
  3. Number of subjects of Significant Abnormal Vital Signs FindingsTime frame: Baseline to Day 8
  4. Number of Participants With Significant Abnormal Laboratory ValuesTime frame: Baseline to Day 8
  5. Number of subjects With Significant Abnormal Electrocardiography (ECG) FindingsTime frame: Baseline,1 hour,4 hour,48 hour,Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.